Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AEG-1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
AEG-1 siRNA is a **small interfering RNA** designed to selectively inhibit the expression of *astrocyte elevated gene-1* (*AEG-1*, also known as *metadherin* or *MTDH*), a gene overexpressed in multiple cancers and implicated in tumor growth, metastasis, angiogenesis, chemoresistance, and epithelial-mesenchymal transition. AEG-1 promotes cancer progression partly by increasing expression of multidrug resistance proteins, supporting the PI3K/Akt and Wnt/β-catenin signaling pathways, and regulating the function of RNA-induced silencing complexes (RISC). Suppression of AEG-1 by siRNA has been shown in preclinical studies to decrease cancer cell proliferation, sensitize tumors to chemotherapeutics like doxorubicin and 5-fluorouracil, reduce metastasis, and reverse EMT phenotypes. Research is primarily at the preclinical stage, with most data from cellular and animal xenograft models[1][2][3][7].
- Other names
- astrocyte elevated gene-1 siRNAmetadherin siRNAMTDH siRNA
02
Targets
MTDH (Metadherin)
Beyond the preview
Go deeper on AEG-1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AEG-1 siRNA.